Loading…
The trial focuses on patients with advanced solid tumors and a TP53 Y220C mutation.
PMV Pharmaceuticals, Inc. announced on 2025-09-10 PMV Pharmaceuticals announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial for rezatapopt, a small molecule, p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
6.2 months median duration of response. 7.6 months median duration of response in ovarian cancer cohort. 109 patients in safety population. 97 patients in efficacy population. 3 (range: 1-10) median number of prior lines of systemic therapy. 3.7% rate of drug discontinuations due to a TRAE. The announcement cited 33% overall response rate, and 43% ORR in ovarian cancer cohort.
PMV Pharmaceuticals, Inc. has a free float of 41,147,900 shares and 53,212,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.